JP2018522581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522581A5 JP2018522581A5 JP2018516634A JP2018516634A JP2018522581A5 JP 2018522581 A5 JP2018522581 A5 JP 2018522581A5 JP 2018516634 A JP2018516634 A JP 2018516634A JP 2018516634 A JP2018516634 A JP 2018516634A JP 2018522581 A5 JP2018522581 A5 JP 2018522581A5
- Authority
- JP
- Japan
- Prior art keywords
- pamphlet
- international publication
- lsd1 inhibitor
- biomarker
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 35
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 claims description 31
- 239000000090 biomarker Substances 0.000 claims description 19
- 102100032420 Protein S100-A9 Human genes 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 9
- 208000015114 central nervous system disease Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 102100032442 Protein S100-A8 Human genes 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- XBBRLCXCBCZIOI-DLBZAZTESA-N vafidemstat Chemical group O1C(N)=NN=C1CN[C@H]1[C@H](C=2C=CC(OCC=3C=CC=CC=3)=CC=2)C1 XBBRLCXCBCZIOI-DLBZAZTESA-N 0.000 claims 3
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000028172 protozoa infectious disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382310 | 2015-06-12 | ||
| EP15382310.9 | 2015-06-12 | ||
| EP15382369.5 | 2015-07-17 | ||
| EP15382369 | 2015-07-17 | ||
| PCT/EP2016/063368 WO2016198649A1 (en) | 2015-06-12 | 2016-06-10 | Biomarkers associated with lsd1 inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522581A JP2018522581A (ja) | 2018-08-16 |
| JP2018522581A5 true JP2018522581A5 (https=) | 2019-07-11 |
| JP6855466B2 JP6855466B2 (ja) | 2021-04-07 |
Family
ID=56345081
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516634A Expired - Fee Related JP6855466B2 (ja) | 2015-06-12 | 2016-06-10 | Ｌｓｄ１阻害剤に関連するバイオマーカーおよびそれらの使用 |
| JP2017565305A Expired - Fee Related JP6411680B1 (ja) | 2015-06-12 | 2017-06-09 | Ｌｓｄ１阻害剤を用いて多発性硬化症を処置する方法 |
| JP2018177879A Pending JP2019023202A (ja) | 2015-06-12 | 2018-09-21 | Ｌｓｄ１阻害剤を用いて多発性硬化症を処置する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017565305A Expired - Fee Related JP6411680B1 (ja) | 2015-06-12 | 2017-06-09 | Ｌｓｄ１阻害剤を用いて多発性硬化症を処置する方法 |
| JP2018177879A Pending JP2019023202A (ja) | 2015-06-12 | 2018-09-21 | Ｌｓｄ１阻害剤を用いて多発性硬化症を処置する方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20180284095A1 (https=) |
| EP (1) | EP3307909A1 (https=) |
| JP (3) | JP6855466B2 (https=) |
| KR (2) | KR20180011331A (https=) |
| CN (2) | CN107849611A (https=) |
| AU (2) | AU2016275702A1 (https=) |
| BR (1) | BR112018075310A2 (https=) |
| CA (1) | CA2987876A1 (https=) |
| CY (1) | CY1121988T1 (https=) |
| DK (1) | DK3307267T3 (https=) |
| HR (1) | HRP20191121T1 (https=) |
| HU (1) | HUE043954T2 (https=) |
| IL (2) | IL256208A (https=) |
| LT (1) | LT3307267T (https=) |
| MX (2) | MX2017015922A (https=) |
| MY (1) | MY190849A (https=) |
| PT (1) | PT3307267T (https=) |
| RU (1) | RU2768120C2 (https=) |
| SG (1) | SG10201911989SA (https=) |
| SM (1) | SMT201900353T1 (https=) |
| TR (1) | TR201909353T4 (https=) |
| WO (2) | WO2016198649A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| AU2016275702A1 (en) * | 2015-06-12 | 2017-12-21 | Oryzon Genomics, S.A. | Biomarkers associated with LSD1 inhibitors and uses thereof |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| CA3017408C (en) | 2016-03-15 | 2025-08-19 | Oryzon Genomics, S.A. | LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIS |
| RS58951B1 (sr) | 2016-06-10 | 2019-08-30 | Oryzon Genomics Sa | Lečenje multiple skleroze |
| JP2019128317A (ja) * | 2018-01-26 | 2019-08-01 | 学校法人同志社 | 多発性硬化症の診断マーカー又は診断キット |
| JP2021522305A (ja) * | 2018-05-04 | 2021-08-30 | オリソン ヘノミクス，ソシエダ アノニマ | 安定した医薬製剤 |
| WO2021125732A1 (ko) * | 2019-12-19 | 2021-06-24 | 재단법인 대구경북과학기술원 | 콧물 시료를 이용한 경도 인지 장애의 진단용 바이오마커 조성물 및 이를 이용한 경도 인지 장애의 진단 방법 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| AU6168396A (en) * | 1995-06-07 | 1996-12-30 | Athena Neurosciences, Inc. | Method for identifying alzheimer's disease therapeutics usin g transgenic animal models |
| EP1193261A1 (en) * | 2000-10-02 | 2002-04-03 | Warner-Lambert Company | New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
| WO2007021839A2 (en) | 2005-08-10 | 2007-02-22 | Johns Hopkins University | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors |
| EP2142287A4 (en) | 2007-04-13 | 2012-05-23 | Univ Johns Hopkins | INHIBITORS OF LYSINPECIFIC DEMETHYLASE |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8895526B2 (en) * | 2009-03-27 | 2014-11-25 | Cold Spring Harbor Laboratory | Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| EP2258865A1 (en) * | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
| JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| EP2467359A4 (en) | 2009-08-18 | 2013-01-09 | Univ Johns Hopkins | (BIS-) UREA- AND (BIS-) THIOMINE COMPOUNDS AS EPIGENE MODULATORS OF THE LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF DISEASE TREATMENT THEREWITH |
| US8859555B2 (en) | 2009-09-25 | 2014-10-14 | Oryzon Genomics S.A. | Lysine Specific Demethylase-1 inhibitors and their use |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| CA2796726C (en) | 2010-04-19 | 2021-02-16 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| BR112012027062B8 (pt) | 2010-04-20 | 2021-05-25 | Fond Ieo | composto, processo para a preparação de um composto e usos do mesmo |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| BR112013002164B1 (pt) | 2010-07-29 | 2021-11-09 | Oryzon Genomics S.A. | Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica |
| WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| PH12013501871A1 (en) | 2011-03-25 | 2019-06-03 | Glaxosmithkline Ip No 2 Ltd | Cyclopropylamines as lsd1 inhibitors |
| PE20141202A1 (es) | 2011-08-09 | 2014-10-03 | Takeda Pharmaceutical | Compuesto de ciclopropanoamina |
| SI2744330T1 (sl) | 2011-08-15 | 2020-11-30 | University Of Utah Research Foundation | Substituirani (E)-N'-(1-feniletiliden) benzohidrazidni analogi kot inhibitorji histon-demetilaze |
| JP6046154B2 (ja) | 2011-10-20 | 2016-12-14 | オリソン ヘノミクス エセ． アー． | Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物 |
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| CA2887598A1 (en) | 2012-10-12 | 2014-04-17 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
| WO2014084298A1 (ja) | 2012-11-28 | 2014-06-05 | 京都府公立大学法人 | リシン構造を有するｌｓｄ1選択的阻害薬 |
| EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| CN103054869A (zh) | 2013-01-18 | 2013-04-24 | 郑州大学 | 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用 |
| WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
| WO2014194280A2 (en) | 2013-05-30 | 2014-12-04 | The Board of Regents of the Nevada System of Higher Education on behalf of the University of | Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells |
| BR112015032113B1 (pt) | 2013-06-19 | 2019-01-29 | University Of Utah Research Foundation | análogos de (e)-n’-(1-feniletilideno)benzohidrazida substituídos como inibidores de histona demetilase |
| CN103319466B (zh) | 2013-07-04 | 2016-03-16 | 郑州大学 | 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用 |
| ES2734209T3 (es) | 2013-08-06 | 2019-12-04 | Imago Biosciences Inc | Inhibidores de KDM1A para el tratamiento de enfermedades |
| US9186391B2 (en) | 2013-08-29 | 2015-11-17 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
| WO2015031564A2 (en) | 2013-08-30 | 2015-03-05 | University Of Utah | Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors |
| CA3161836A1 (en) | 2013-12-11 | 2015-06-18 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| WO2015120281A1 (en) | 2014-02-07 | 2015-08-13 | Musc Foundation For Research Development | Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators |
| JP6602779B2 (ja) | 2014-02-13 | 2019-11-06 | インサイト・コーポレイション | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| EP3105218B1 (en) | 2014-02-13 | 2019-09-25 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| CA2941716A1 (en) | 2014-03-07 | 2015-09-11 | The Johns Hopkins University | Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs) |
| CN103893163B (zh) | 2014-03-28 | 2016-02-03 | 中国药科大学 | 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用 |
| MY180575A (en) | 2014-04-11 | 2020-12-02 | Takeda Pharmaceuticals Co | Cyclopropanamine compound and use thereof |
| CN103961340B (zh) | 2014-04-30 | 2019-06-25 | 南通中国科学院海洋研究所海洋科学与技术研究发展中心 | 一类lsd1抑制剂及其应用 |
| KR102400920B1 (ko) | 2014-05-01 | 2022-05-20 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
| WO2015181380A1 (en) | 2014-05-30 | 2015-12-03 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Cyclopropylamine compounds as histone demethylase inhibitors |
| CN104119280B (zh) | 2014-06-27 | 2016-03-16 | 郑州大学 | 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用 |
| DK3160956T3 (da) | 2014-06-27 | 2020-08-31 | Celgene Quanticel Res Inc | Inhibitorer af lysin-specifik demethylase-1 |
| FI3511319T3 (fi) | 2014-07-03 | 2023-07-20 | Celgene Quanticel Res Inc | Lysiinispesifisen demetylaasi-1:n inhibiittoreita |
| JP6525422B2 (ja) | 2014-07-03 | 2019-06-05 | セルジーン クオンティセル リサーチ，インク． | リジン特異的なデメチラーゼ−１の阻害剤 |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| AU2015311805B2 (en) | 2014-09-05 | 2020-04-02 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
| AU2016275702A1 (en) * | 2015-06-12 | 2017-12-21 | Oryzon Genomics, S.A. | Biomarkers associated with LSD1 inhibitors and uses thereof |
-
2016
- 2016-06-10 AU AU2016275702A patent/AU2016275702A1/en not_active Abandoned
- 2016-06-10 WO PCT/EP2016/063368 patent/WO2016198649A1/en not_active Ceased
- 2016-06-10 SG SG10201911989SA patent/SG10201911989SA/en unknown
- 2016-06-10 US US15/735,377 patent/US20180284095A1/en not_active Abandoned
- 2016-06-10 JP JP2018516634A patent/JP6855466B2/ja not_active Expired - Fee Related
- 2016-06-10 KR KR1020187001221A patent/KR20180011331A/ko not_active Withdrawn
- 2016-06-10 EP EP16734564.4A patent/EP3307909A1/en not_active Withdrawn
- 2016-06-10 CA CA2987876A patent/CA2987876A1/en not_active Abandoned
- 2016-06-10 MX MX2017015922A patent/MX2017015922A/es unknown
- 2016-06-10 CN CN201680045398.8A patent/CN107849611A/zh active Pending
-
2017
- 2017-06-09 RU RU2019100037A patent/RU2768120C2/ru active
- 2017-06-09 MX MX2017015921A patent/MX2017015921A/es active IP Right Grant
- 2017-06-09 JP JP2017565305A patent/JP6411680B1/ja not_active Expired - Fee Related
- 2017-06-09 CN CN201780002630.4A patent/CN107921029B/zh not_active Expired - Fee Related
- 2017-06-09 AU AU2017277751A patent/AU2017277751B2/en not_active Ceased
- 2017-06-09 WO PCT/EP2017/064206 patent/WO2017212061A1/en not_active Ceased
- 2017-06-09 MY MYPI2017001810A patent/MY190849A/en unknown
- 2017-06-09 KR KR1020187001123A patent/KR102372194B1/ko not_active Expired - Fee Related
- 2017-06-09 TR TR2019/09353T patent/TR201909353T4/tr unknown
- 2017-06-09 HU HUE17735004A patent/HUE043954T2/hu unknown
- 2017-06-09 HR HRP20191121TT patent/HRP20191121T1/hr unknown
- 2017-06-09 LT LTEP17735004.8T patent/LT3307267T/lt unknown
- 2017-06-09 PT PT17735004T patent/PT3307267T/pt unknown
- 2017-06-09 SM SM20190353T patent/SMT201900353T1/it unknown
- 2017-06-09 DK DK17735004.8T patent/DK3307267T3/da active
- 2017-06-09 BR BR112018075310-6A patent/BR112018075310A2/pt not_active Application Discontinuation
- 2017-12-10 IL IL256208A patent/IL256208A/en unknown
- 2017-12-10 IL IL256207A patent/IL256207B/en unknown
-
2018
- 2018-09-21 JP JP2018177879A patent/JP2019023202A/ja active Pending
-
2019
- 2019-06-26 CY CY20191100663T patent/CY1121988T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522581A5 (https=) | ||
| PH12019501707A1 (en) | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor | |
| CN111601791A (zh) | Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用 | |
| JP2016516699A5 (https=) | ||
| NO20083568L (no) | Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser | |
| MX367543B (es) | MOLÉCULAS DE ÁCIDO NUCLEICO PARA LA REDUCCIÓN DE ARNm DE PAPD5 O PAPD7 PARA TRATAR LA INFECCIÓN POR HEPATITIS B. | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| TN2018000218A1 (en) | Indole carboxamides compounds useful as kinase inhibitors. | |
| WO2015200680A3 (en) | Prmt5 inhibitors and uses thereof | |
| JP2016514159A5 (https=) | ||
| JP2011502153A5 (https=) | ||
| NZ602125A (en) | Uses of dgat1 inhibitors | |
| JP2016539157A5 (https=) | ||
| JP2017511377A5 (https=) | ||
| CN109790155A (zh) | 噻吩化合物及其合成方法和其在医药上的应用 | |
| JP2019501140A5 (https=) | ||
| BR112018075310A2 (pt) | metódo de tratamento de esclerose múltipla empregando um inibidor de lsd1 | |
| WO2011026911A8 (en) | Bipyridines useful for the treatment of proliferative diseases | |
| EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
| JP2019519533A5 (https=) | ||
| WO2016109217A3 (en) | Btk inhibitors | |
| NZ762437A (en) | Novel heterocyclic compounds as cdk8/19 inhibitors | |
| MX2015000746A (es) | Terapia de combinacion de inhibidores para el receptor del factor de crecimiento insulinico tipo 1 (igf1r) y fosfatidilinositol 3-cinasa (pi3k). | |
| MX389330B (es) | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. | |
| EP4512473A3 (en) | Methods of treating behavior alterations |